Regulatory approvals, trial data, and major licensing deals in 2026 are accelerating subcutaneous biologics, cutting patient burden and reshaping biopharma strategy.
|Articles|October 4, 2019
GSK Completes Retrofit of Maryland Facility
Author(s)BioPharm International Editors
GSK invested $139 million to its Rockville, MD site to support demand for Benlysta.
Advertisement
GSK marked the completion of construction of a biopharmaceutical manufacturing facility at its Rockville, MD site with a ceremony on Oct. 3, 2019. The $139 million investment into the Rockville site, originally
The investment was used to retrofit an existing facility at the Rockville manufacturing site and covered demolition of existing suites, engineering, installation, and validation of equipment.
The expansion increased manufacturing capacity at the site by 50% and created 100 new jobs, bringing the total number of GSK jobs in the Rockville, MD area to approximately 1000.
Benlysta was launched in 2011 and in April 2019, FDA also approved its expanded use for the treatment of patients aged five years and older with active, autoantibody-positive SLE who are receiving standard therapy.
Source:
Advertisement
Related to this article
Dualitas will screen over 300,000 bispecific combinations for Roche, backing a deal worth up to $1 billion in immunology research.
Today’s biopharma news highlights GSK’s myeloma strategy, Insilico’s AI longevity research, and innovations that may improve future treatment outcomes.
GSK's new trispecific TCE targets 2 tumor antigens plus T cells, aiming to improve on the tolerability of current myeloma therapies.
This episode of the BioPharm Brief highlights Roche’s Tam-Peli phase 3 survival data in relapsed small-cell lung cancer, Cellectis’ shift to in vivo gene editing for lipid disorders, and Phio Pharmaceuticals’ FDA briefing package for PH-762 in cutaneous squamous cell carcinoma.
Tambotatug pelitecan (Tam-Peli), a B7-H3-targeted antibody-drug conjugate, is the second of at least three B7-H3-targeted ADCs to post positive late-stage data in relapsed small-cell lung cancer this year.
Four cell therapy developers have pulled back from ex vivo manufacturing in the past month — ArsenalBio, TScan Therapeutics, and Cellectis all pivoted to in vivo approaches, while Bristol Myers Squibb terminated its manufacturing partnership with automation specialist Cellares after determining its platform couldn't meet requirements for commercial Breyanzi production, triggering layoffs.
The BioPharm Brief covers Resolution Therapeutics’ completed enrollment of RTX001 in the EMERALD trial, Samsung Biologics’ $262 million manufacturing deal, and CordenPharma’s $80 million investment to expand sterile injectable capacity.
Advertisement
Advertisement